Company Overview and News

 
KNR Constructions rises 6% on sanction from bank to finance HAM project worth Rs 1,234cr

2018-09-14 moneycontrol
Shares of KNR Constructions rose 6.5 percent intraday Friday after company received bank sanction to finance HAM Project (Hybrid Annuity Mode) worth Rs 1,234 crore.
KNRCON 532942

 
KNR Constructions Limited - Updates

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - Shareholders meeting

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - Investor Presentation

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - AGM/Book Closure

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - Outcome of Board Meeting

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
KNR Constructions up 3% on sanction letters from banks for 3 projects

2018-07-09 moneycontrol
The shares of KNR Constructions gained 3 percent in intraday Monday following the receipt of sanction letters from banks to finance their projects.
KNRCON 532942

 
KNR Constructions Limited - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KNRCON 532942

 
Why road-construction stocks are struggling

2018-07-08 premium.thehindubusinessline
Till recently, stocks in the road construction space had enjoyed a good run on the bourses, all thanks to the healthy award of contracts by the National Highways Authority of India (NHAI), which ensured revenue visibility for many companies, at least for the next couple of years.
KNRCON SADBHAV 532942 532710

23
Closing Bell: Sensex loses 115 pts, Nifty ends below 10,750; ITC, LT shares drag

2018-06-21 moneycontrol
Global Update: Asian markets closed mixed as investors monitor trade developments between world's largest economies US and China. China's Shanghai Composite, Hong Kong's Hang Seng and South Korea's Kospi closed down over a percent while Japan's Nikkei gained 0.6 percent and Australia's ASX 200 rose 1 percent.
INDIANB 500325 533096 RELIANCE IDBI 512573 532814 532832 533278 JUSTDIAL 535648 RIGD HDFCBANK CLNDY RLNIY UBNC 500116 AVANTI 534690 IBN 532942 539207 KNRCON ICICIBANK LAKSHVILAS HDB 532174 500180 ADANIPOWER COALINDIA JSTQY MANPASAND IBREALEST

16
Market Live: Sensex falls 100 pts, Nifty below 10,750; crude dips 2% ahead of OPEC meet

2018-06-21 moneycontrol
Further, reports of the bank appointing a law firm and risk assessment company to assist the independent enquiry against its CEO soothed market investors.
500325 534690 IBN RELIANCE 532942 539207 KNRCON ICICIBANK LAKSHVILAS HDB 532174 500180 RIGD HDFCBANK MANPASAND RLNIY

16
Market Live: Midcap underperforms Sensex; Brent crude dips 1% ahead of OPEC meet

2018-06-21 moneycontrol
Oil prices dipped as Iran signaled it could be won over to a small rise in OPEC crude output, likely paving the road for the producer cartel to agree on a supply increase during a meeting on June 22.
INDIGO 500325 534690 IBN RELIANCE 532942 539448 539207 KNRCON ICICIBANK LAKSHVILAS HDB 532174 500180 RIGD HDFCBANK MANPASAND RLNIY

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

6h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...